Cellebrite DI Ltd. CLBT
12.45 USD +0.07 (+0.57%)
At closeNov 6, 2026, 4:00 PM EST
12.45 0.00 0.00%
After hours · Nov 6, 4:00 PM ET
12.18 Day range 12.51
10.44 52-week range 19.28
- YTD
- -30.95%
- 1 year
- -18.41%
News
prnewswire.com Cellebrite Appoints Rogerio Rizzi Executive Vice President of Corporate Strategy and Development Former Okta and SAP strategy leader brings AI, platform and M&A expertise to accelerate Cellebrite's growth TYSONS CORNER, Va. and PETAH TIKVA, Israel, Nov. 5, 2026 /PRNewswire/ -- Cellebrite…benzinga.com Lake Street Maintains Buy on Cellebrite DI, Lowers Price Target to $15 Lake Street analyst Eric Martinuzzi maintains Cellebrite DI (NASDAQ:CLBT) with a Buy and lowers the price target from $21 to $15.
benzinga.com JP Morgan Maintains Overweight on Cellebrite DI, Lowers Price Target to $16 JP Morgan analyst Brian Essex maintains Cellebrite DI (NASDAQ:CLBT) with a Overweight and lowers the price target from $20 to $16.
benzinga.com DA Davidson Maintains Buy on Cellebrite DI, Lowers Price Target to $15 DA Davidson analyst Rudy Kessinger maintains Cellebrite DI (NASDAQ:CLBT) with a Buy and lowers the price target from $22 to $15.
benzinga.com Needham Maintains Buy on Cellebrite DI, Lowers Price Target to $12.5 Needham analyst Mike Cikos maintains Cellebrite DI (NASDAQ:CLBT) with a Buy and lowers the price target from $15 to $12.5.
benzinga.com 12 Information Technology Stocks Moving In Thursday's Intraday Session Gainers BGIN Blockchain (NASDAQ:BGIN) stock rose 38.8% to $2.36 during Thursday's regular session. The company's market cap stands at $192.3 million. Iveda Solutions (NASDAQ:IVDA) shares moved…
benzinga.com Cellebrite Shares Plunge Thursday: What's Driving the Move? Shares of Cellebrite are trading sharply lower on Thursday following the release of second-quarter financial results that missed top-line expectations alongside downgraded revenue guidance for the…
benzinga.com Gold Down 2%; Cisco Shares Tumble After Q4 Results US stocks mixed, Nasdaq up more than 150 points. Dow down 0.16% to 53,682.87, Nasdaq up 0.61% to 26,749.51, S&P 500 up 0.45% to 7,783.09. Real estate sector up 1.2%, energy down 1%. Cisco shares down…
benzinga.com Full Transcript: Cellebrite DI Q2 2026 Earnings Call Cellebrite DI (NASDAQ:CLBT) reported second-quarter financial results on Thursday. The transcript from the company's second-quarter earnings call has been provided below. This transcript is brought…
benzinga.com Dow Gains Over 100 Points; Producer Prices Unchanged In July US stocks up, Dow gains over 100 points. Real estate sector rises, energy sector falls. Producer Price Index unchanged, inflation rate down.
benzinga.com 12 Information Technology Stocks Moving In Thursday's Pre-Market Session Gainers Yxt.Com Group Holding (NASDAQ:YXT) stock moved upwards by 47.5% to $6.68 during Thursday's pre-market session. The company's market cap stands at $27.6 million. As per the press release, H1…benzinga.com Cellebrite DI Lowers FY2026 Sales Guidance from $565.000M-$571.000M to $555.000M-$561.000M vs $568.048M Est Cellebrite DI (NASDAQ:CLBT) lowers FY2026 sales outlook from $565.000 million-$571.000 million to $555.000 million-$561.000 million vs $568.048 million estimate.
benzinga.com Cellebrite DI Sees Q3 Sales $145.000M-$148.000M vs $150.298M Est Cellebrite DI (NASDAQ:CLBT) sees Q3 sales of $145.000 million-$148.000 million vs $150.298 million analyst estimate.
benzinga.com Cellebrite DI Q2 Adj. EPS $0.11, Inline, Sales $131.138M Miss $131.874M Estimate Cellebrite DI (NASDAQ:CLBT) reported quarterly earnings of $0.11 per share which met the analyst consensus estimate. This is a 8.33 percent decrease over earnings of $0.12 per share from the same…
benzinga.com DA Davidson Maintains Buy on Cellebrite DI, Raises Price Target to $22 DA Davidson analyst Rudy Kessinger maintains Cellebrite DI (NASDAQ:CLBT) with a Buy and raises the price target from $20 to $22.
benzinga.com DA Davidson Initiates Coverage On Cellebrite DI with Buy Rating, Announces Price Target of $20 DA Davidson analyst Rudy Kessinger initiates coverage on Cellebrite DI (NASDAQ:CLBT) with a Buy rating and announces Price Target of $20.
benzinga.com Needham Maintains Buy on Cellebrite DI, Lowers Price Target to $15 Needham analyst Mike Cikos maintains Cellebrite DI (NASDAQ:CLBT) with a Buy and lowers the price target from $18 to $15.
benzinga.com Cellebrite DI Q1 2026 Earnings Call Transcript
benzinga.com Earnings Scheduled For May 14, 2026 benzinga.com Cellebrite Announces FedRAMP High Authorization For Its Cellebrite Government Cloud Platform Cellebrite DI Ltd. (NASDAQ:CLBT), a global leader in AI-powered Digital Investigative and Intelligence solutions for the public and private sectors, today announced that its Cellebrite Government…
benzinga.com 12 Information Technology Stocks Moving In Friday's After-Market Session benzinga.com Needham Maintains Buy on Cellebrite DI, Lowers Price Target to $18 Needham analyst Mike Cikos maintains Cellebrite DI (NASDAQ:CLBT) with a Buy and lowers the price target from $24 to $18.
benzinga.com Cellebrite DI Sees FY2026 Sales $565.000M-$571.000M vs $554.864M Est Cellebrite DI (NASDAQ:CLBT) sees FY2026 sales of $565.000 million-$571.000 million vs $554.864 million analyst estimate.
benzinga.com Cellebrite DI Sees Q1 Sales $126.000M-$128.000M vs $130.637M Est Cellebrite DI (NASDAQ:CLBT) sees Q1 sales of $126.000 million-$128.000 million vs $130.637 million analyst estimate.
benzinga.com Cellebrite DI: Q4 Earnings Insights benzinga.com Cellebrite DI Q4 Adj. EPS $0.14, Inline, Sales $128.821M Beat $126.556M Estimate Cellebrite DI (NASDAQ:CLBT) reported quarterly earnings of $0.14 per share which met the analyst consensus estimate. This is a 40 percent increase over earnings of $0.10 per share from the same…
benzinga.com Earnings Scheduled For February 11, 2026
benzinga.com Security Tech Check-In: Analyst Insights From 12 Companies Ahead Of The 'Quiet Period' Needham analysts met with 12 companies before quiet period. Ratings and price targets by analyst Mike Cikos.
benzinga.com These Fast-Rising Tech Stocks Are Surging in Growth Scores This Week benzinga.com JP Morgan Maintains Overweight on Cellebrite DI, Raises Price Target to $24 JP Morgan analyst Brian Essex maintains Cellebrite DI (NASDAQ:CLBT) with a Overweight and raises the price target from $23 to $24.
benzinga.com Lake Street Maintains Buy on Cellebrite DI, Raises Price Target to $23 Lake Street analyst Eric Martinuzzi maintains Cellebrite DI (NASDAQ:CLBT) with a Buy and raises the price target from $22 to $23.
benzinga.com B of A Securities Maintains Buy on Cellebrite DI, Raises Price Target to $25 B of A Securities analyst Tal Liani maintains Cellebrite DI (NASDAQ:CLBT) with a Buy and raises the price target from $24 to $25.
benzinga.com 12 Information Technology Stocks Moving In Thursday's Intraday Session
benzinga.com Spectrum Brands Posts Upbeat Q3 Earnings, Joins Ondas Holdings, Firefly Aerospace, Cellebrite DI And Other Big Stocks Moving Higher On Thursday
benzinga.com AutoZone To Rally More Than 12%? Here Are 10 Top Analyst Forecasts For Thursday
benzinga.com 12 Information Technology Stocks Moving In Thursday's Pre-Market Session benzinga.com Needham Maintains Buy on Cellebrite DI, Raises Price Target to $24 Needham analyst Mike Cikos maintains Cellebrite DI (NASDAQ:CLBT) with a Buy and raises the price target from $22 to $24.
benzinga.com Why Cisco Shares Are Trading Higher By 7%; Here Are 20 Stocks Moving Premarket
benzinga.com 12 Information Technology Stocks Moving In Wednesday's After-Market Session
benzinga.com Earnings Scheduled For November 12, 2025 benzinga.com JP Morgan Maintains Overweight on Cellebrite DI, Raises Price Target to $23 JP Morgan analyst Brian Essex maintains Cellebrite DI (NASDAQ:CLBT) with a Overweight and raises the price target from $20 to $23.
benzinga.com Applied Materials To Rally Around 17%? Here Are 10 Top Analyst Forecasts For Friday benzinga.com Lake Street Maintains Buy on Cellebrite DI, Lowers Price Target to $22 Lake Street analyst Eric Martinuzzi maintains Cellebrite DI (NASDAQ:CLBT) with a Buy and lowers the price target from $24 to $22.
benzinga.com Needham Maintains Buy on Cellebrite DI, Lowers Price Target to $18 Needham analyst Mike Cikos maintains Cellebrite DI (NASDAQ:CLBT) with a Buy and lowers the price target from $24 to $18.
benzinga.com Cellebrite DI Sees Q3 Sales $121.000M-$126.000M vs $124.357M Est Cellebrite DI (NASDAQ:CLBT) sees Q3 sales of $121.000 million-$126.000 million vs $124.357 million analyst estimate.
benzinga.com Cellebrite DI Lowers FY2025 Sales Guidance from $470.000M-$485.000M to $465.000M-$475.000M vs $474.952M Est Cellebrite DI (NASDAQ:CLBT) lowers FY2025 sales outlook from $470.000 million-$485.000 million to $465.000 million-$475.000 million vs $474.952 million estimate.
benzinga.com Cellebrite DI Q2 Adj. EPS $0.12 Beats $0.10 Estimate, Sales $113.276M Beat $112.206M Estimate Cellebrite DI (NASDAQ:CLBT) reported quarterly earnings of $0.12 per share which beat the analyst consensus estimate of $0.10 by 15.38 percent. This is a 20 percent increase over earnings of $0.10…
benzinga.com Earnings Scheduled For August 14, 2025
benzinga.com Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet The Benzinga Stock Whisper Index looks at five stocks seeing increased attention from readers during the week and a look at what could be causing the increased interest.benzinga.com Needham Reiterates Buy on Cellebrite DI, Maintains $24 Price Target Needham analyst Mike Cikos reiterates Cellebrite DI (NASDAQ:CLBT) with a Buy and maintains $24 price target.
